Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurobindo Takes Pole Position In Less Genericized Portuguese Market

Executive Summary

India’s Aurobindo Pharma has catapulted to the top spot in the Portuguese generic market with the buyout of Generis Farmacêutica SA and hopes to cash in on its extensive portfolio and brand loyalty to drive growth.

You may also be interested in...



Big Statement By Aurobindo As It Seals $1bn Sandoz US Deal

Aurobindo is betting big, buying certain portions of Sandoz’s US portfolio in a deal potentially worth $1bn. The acquisition positions the Indian firm in the top league in the overall US generics space by Rx and also segments like dermatology, but much could depend on how effectively Aurobindo delivers on value creation potential amid ongoing price pressures.

Aurobindo Aims For Europe Growth With Apotex Acquisitions

The Indian drug maker is handing over €74m to Canada's Apotex, buying the latter's operations in Poland, the Czech Republic, the Netherlands, Spain and Belgium and adding over 200 generics and more than 80 OTC products to its portfolio.

Aurobindo Aims For Europe Growth With Apotex Acquisitions

The Indian drug maker is handing over €74m to Canada's Apotex, buying the latter's operations in Poland, the Czech Republic, the Netherlands, Spain and Belgium and adding over 200 generics and more than 80 OTC products to its portfolio.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134211

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel